The Karyopharm Therapeutics Inc (KPTI) Receives $14.17 Average Price Target from Analysts

The Karyopharm Therapeutics Inc (KPTI) Receives $14.17 Average Price Target from Analysts”

Karyopharm Therapeutics Inc. has a 12-month low of $6.27 and a 12-month high of $14.63. The stock was sold at an average price of $11.00, for a total transaction of $1,298.00. On average, equities research analysts anticipate that Karyopharm Therapeutics will post ($2.68) EPS for the current fiscal year. The firm has "Buy" rating given on Wednesday, September 9 by Jefferies.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has been the object of insider selling activity recently. The rating was upgraded by Jefferies on Tuesday, August 30 to "Buy". After $-0.64 actual earnings per share reported by Karyopharm Therapeutics Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth. They now have a Dollars 42 price target on the stock. Finally, Canaccord Genuity set a $18.00 price target on shares of Karyopharm Therapeutics and gave the company a "buy" rating in a research note on Tuesday, August 8th. Cantor Fitzgerald reiterated an "overweight" rating and set a $18.00 price objective on shares of Karyopharm Therapeutics in a research note on Monday, May 15th. The company was maintained on Wednesday, August 12 by MLV.

Petroleum & Resources Corp increased Exxon Mobil Corp (XOM) stake by 0.33% reported in 2016Q4 SEC filing. Envestnet Asset Mgmt Incorporated has 96 shares for 0% of their portfolio. Bank of New York Mellon Corp now owns 181,602 shares of the company's stock valued at $2,332,000 after purchasing an additional 69,315 shares during the period. About 432,710 shares traded or 146.40% up from the average. The value of the company's investment in Karyopharm Therapeutics Inc. decreased from $3,531,000 to $2,715,000 a change of 23.1% quarter to quarter. The company reported ($0.64) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.64). Karyopharm Therapeutics earned a coverage optimism point of 0.13 on Accern's range. The stock's market capitalization is 498.25M. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It now has negative earnings. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Investors sentiment increased to 1.56 in 2016 Q4. Its up 0.40, from 1.16 in 2016Q3. Endurance Wealth Management Inc. boosted its position in shares of Karyopharm Therapeutics by 166.7% in the third quarter. Barclays Public Ltd Company stated it has 6,266 shares. 102,556 are held by Morgan Stanley. Credit Suisse Ag has 17,859 shares. Karyopharm Therapeutics Inc. had 22 analyst reports since August 11, 2015 according to SRatingsIntel. Vanguard Group Inc. raised its holdings in shares of Karyopharm Therapeutics by 31.1% in the 2nd quarter. 6,994 are held by Blackrock Group.

News articles about Karyopharm Therapeutics (NASDAQ:KPTI) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Zacks Lowered stocks of Karyopharm Therapeutics from a "buy" recommendation to a "hold" recommendation in a study on Tue, Jul 18th. New York State Common Retirement Fund reported 29,430 shares stake. Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. Cam Gru Holdg A S holds 0% of its portfolio in Karyopharm Therapeutics Inc (NASDAQ:KPTI) for 13,000 shares. Bnp Paribas Arbitrage Sa has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Geode Cap Management Lc has 156,493 shares for 0% of their portfolio. Creative Planning, Kansas-based fund reported 5,700 shares.

The stock increased 3.05% or $0.08 on September 15, reaching $2.7. It has outperformed by 4.49% the S&P500. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Therefore 38% are positive. Robert W. Baird maintained the stock with "Outperform" rating in Friday, April 7 report. The rating was initiated by Macquarie Research with "Underperform" on Wednesday, September 23. A rating of 3 would indicate a Hold recommendation. Goldman Sachs holds 101,702 shares. The rating was initiated by Raymond James on Friday, May 27 with "Outperform". Investors may be watching shares for trading volume that is out of the ordinary. 104 funds opened positions while 652 raised stakes. 4,868 were accumulated by Thomas J Herzfeld Advisors Inc. California-based Elm Advsrs Ltd Liability has invested 0.26% in Exxon Mobil Corporation (NYSE:XOM). Bokf Na accumulated 2.33M shares.

Like this


20 September 2017
Upset New York Giants Fan Hilariously Updates LT Ereck Flowers' Wikipedia Page
As for what the Giants could do to speed up that improvement, McAdoo said everything would be looked at. McAdoo actually did not sound open to any personnel changes at all. "They're not given away".

20 September 2017
FM Zarif Dismisses Trump's "Hollow" Statements on Iran
In turn, Zarif accused Washington of supporting " tyrannical regimes " in the region, and " the criminal Zionist state ". Trump appeared to pave the way towards tearing up the nuclear deal signed in 2015 between six world powers and Iran.

20 September 2017
Billie Jean King thanks sizzling Emma Stone in 'Battle of the Sexes'
Privately, they're fighting their own battles - King with her sexuality and Riggs with a gambling problem. And at the same time preparing for a highly publicised match with Bobby Riggs.

20 September 2017
Darwin Barney leads Blue Jays over Royals 5-2
The Toronto Blue Jays will look to win the set and go for the sweep on Thursday after winning the opener on Tuesday. The Royals needed three different pitchers to get through the inning, but Barney's homer had done its damage.

20 September 2017
Top RSI Trades for Today - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Finally, Victory Capital Management Inc. boosted its holdings in Supernus Pharmaceuticals by 17.7% in the second quarter. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock.

20 September 2017
Canterbury Bulldogs sack coach Des Hasler
An assistant to Hasler at the Bulldogs, Jim Dymock has not shied away from the fact that he would like to coach the club in the past.

20 September 2017
Use of nuclear weapon unthinkable: United Nations chief Antonio Guterres
And Trump said all responsible nations must work together to confront terrorists and "the Islamic extremists that inspire them". With regard to climate change and controlling carbon gas emissions, Guterres said the science was "unassailable".

20 September 2017
OnePlus partners Castelbajac to launch OnePlus 5 limited edition on September 22
As of now, there is information about the availability of the OnePlus 5 JCC Limited Edition outside of Europe. It sports a 5.5-inch Optic AMOLED display with Full HD resolution and Corning Gorilla Glass 5 protection.

20 September 2017
Pac-12 Network to feature plenty of ASU, Arizona men's basketball
Single-game tickets will go on sale to CAF members and season ticket holders, October 2, and to the general public, October 9. The Cougars will play a third consecutive game away from Pullman when they visit UW on January 28 in Seattle (5 p.m., ESPNU).

20 September 2017
Elisabeth Moss wears heels with a message
The acclaimed Hulu series, which began streaming on Hulu in May, received eight awards from 13 nominations, including Outstanding Drama Series.